Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $325.3 million.

  • Axsome Therapeutics' Cash & Equivalents fell 62.35% to $325.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $325.3 million, marking a year-over-year decrease of 62.35%. This contributed to the annual value of $315.4 million for FY2024, which is 1834.32% down from last year.
  • Per Axsome Therapeutics' latest filing, its Cash & Equivalents stood at $325.3 million for Q3 2025, which was down 62.35% from $303.0 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Cash & Equivalents ranged from a high of $437.1 million in Q2 2023 and a low of $73.4 million during Q2 2022
  • Over the past 4 years, Axsome Therapeutics' median Cash & Equivalents value was $315.4 million (recorded in 2024), while the average stood at $286.1 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 49552.18% in 2023, then plummeted by 2777.61% in 2024.
  • Quarter analysis of 4 years shows Axsome Therapeutics' Cash & Equivalents stood at $200.8 million in 2022, then skyrocketed by 92.29% to $386.2 million in 2023, then dropped by 18.34% to $315.4 million in 2024, then grew by 3.15% to $325.3 million in 2025.
  • Its Cash & Equivalents was $325.3 million in Q3 2025, compared to $303.0 million in Q2 2025 and $300.9 million in Q1 2025.